Search
Lacutoclax
go.drugbank.com/drugs/DB21657InvestigationalThe usage of the INN stem '-toclax' in the name indicates that Lacutoclax is a B-cell lymphoma 2 (Bcl-2) inhibitor. Lacutoclax has a monoisotopic molecular weight of 922.36 Da.
Vilzemetkib
go.drugbank.com/drugs/DB21704ExperimentalVilzemetkib has a monoisotopic molecular weight of 642.27 Da. … The usage of the INN stem '-metkib' in the name indicates that Vilzemetkib is a MET (mesenchymal epithelial transition factor) kinase inhibitor.
Albinterferon Alfa-2B
go.drugbank.com/drugs/DB05396InvestigationalHuman Genome Sciences modified interferon alpha to improve its pharmacological properties by using the company's proprietary albumin fusion technology.
RST-001
go.drugbank.com/drugs/DB17843InvestigationalRST-001 is a non-replicating recombinant adeno-associated virus vector containing a fragment of the gene encoding channel rhodopsin-2 protein.
Lilotomab
go.drugbank.com/drugs/DB19076InvestigationalLilotomab is under investigation in clinical trial NCT01796171 (A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-hodgkin Lymphoma).
ALTU-135
go.drugbank.com/drugs/DB05330InvestigationalALTU-135 has been granted orphan drug and fast-track designation as well as CMA Pilot 2 program status by the Food and Drug Administration (FDA). … ALTU-135, the Company's orally administered enzyme replacement therapy for patients with pancreatic insufficiency, is manufactured by blending three drug substance enzymes: lipase, protease and amylase
Nangibotide
go.drugbank.com/drugs/DB16247InvestigationalNangibotide is under investigation in clinical trial NCT04055909 (Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock).
Iodoxamic acid
go.drugbank.com/drugs/DB13539ExperimentalRadiopaque medium used in the diagnosis of gall bladder & bile duct diseases, usually as meglumine salt.
Categories: X-Ray Contrast Media, Iodinated, Watersoluble, Hepatotropic X-Ray Contrast MediaXP12B
go.drugbank.com/drugs/DB04928InvestigationalXP12B is being developed by Xanodyne Pharmaceuticals for the treatment of menorrhagia (heavy menstrual bleeding). It was granted Fast Track status for this indication by the FDA in November 2004.